BigHat Biosciences Raises $75M to Advance AI-Designed Protein Therapeutics
Published in Artificial Intelligence, Drugs development & discovery.
BigHat Biosciences has raised $75 million in Series C financing to advance its AI-designed protein therapeutics and agentic platform for rapid protein design.
The company says the financing will support its clinical-stage pipeline and expand a platform that combines high-throughput experimental data generation with machine learning for protein and antibody design.
Why it matters
Protein therapeutics are difficult to optimize because researchers must balance many properties at once, including binding, specificity, stability and manufacturability. AI paired with rapid laboratory testing could accelerate this iterative design process.
Demonstrated vs. speculative
The demonstrated development is the financing and advancement of BigHat’s clinical-stage and discovery programs. Funding and AI-designed candidates do not by themselves prove clinical efficacy; individual therapies still have to succeed in trials.
If platforms like this reliably improve protein-therapeutic discovery, they could eventually contribute to treatments for cancer, immune disease and age-related disorders. Any direct connection to cryonics remains speculative.
Source: BigHat Biosciences — Series C announcement (September 24, 2026).